Cover Image
市場調查報告書

急性失償心臟衰竭:流行病學、病患人數的市場預測、治療流程、已上市及開發中的藥物分析

Acute Decompensated Heart Failure Forecast and Market Analysis to 2034

出版商 Datamonitor Healthcare 商品編碼 365171
出版日期 內容資訊 英文 95 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
急性失償心臟衰竭:流行病學、病患人數的市場預測、治療流程、已上市及開發中的藥物分析 Acute Decompensated Heart Failure Forecast and Market Analysis to 2034
出版日期: 2018年02月15日 內容資訊: 英文 95 Pages
簡介

新的血管擴張劑的Reasanz及ularitide,通用化發展,隱藏著再活化已成熟的急性失償心臟衰竭 (ADHF)的市場的可能性。

本報告提供急性失償心臟衰竭治療藥趨勢調查,市場定義和概要,疾病定義與診斷,處方趨勢,主要的已上市產品簡介,開發後期的開發平台趨勢等彙整資料。

預測:急性失償心臟衰竭

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • Reasanz (serelaxin)
  • Simdax (levosimendan)
  • Ularitide
  • 主要調查技術

治療:急性失償心臟衰竭

  • 摘要整理
  • 主要調查技術
  • 疾病定義與診斷
  • 各國治療樹
  • 處方趨勢

流行病學:急性失償心臟衰竭

  • 摘要整理
  • 資訊來源、調查手法
  • 預測
  • 流行病學者分析

已上市藥物:急性失償心臟衰竭

  • 摘要整理
  • 產品概要
  • 產品簡介:Natrecor
  • 產品簡介:Simdax

開發平台:急性失償心臟衰竭

  • 摘要整理
  • 臨床實驗平台概要
  • 產品簡介 (開發後期):Reasanz
  • 產品簡介 (開發後期):ularitide

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC13163

Disease Overview

Acute decompensated heart failure (ADHF) is defined as the sudden worsening of heart failure symptoms (mainly edema, dyspnea, and fatigue), which results in severe respiratory distress. ADHF is categorized into hemodynamic stages based on the degree of perfusion and pulmonary capillary wedge pressure. Despite improvements in treatment, ADHF is a burdensome disease associated with high hospitalization and mortality rates in the elderly population.

Recent events and opinion:

  • ADHF treatment is focused on hemodynamic stabilization and alleviation of symptoms.
  • Datamonitor Healthcare estimates that in 2016, there were 1.2 million diagnosed incident cases of ADHF in the US, Japan, and five major EU markets.
  • Natrecor and Simdax have had limited success in the highly genericized ADHF market.
  • Discontinuations of ularitide and Reasanz have left the ADHF pipeline bare.

TABLE OF CONTENTS

TREATMENT: ACUTE DECOMPENSATED HEART FAILURE (Published on 19 January 2018)

  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: ACUTE DECOMPENSATED HEART FAILURE (Published on 18 January 2018)

  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • SOURCES AND METHODOLOGY
  • FORECAST
  • EPIDEMIOLOGIST INSIGHT
  • STRENGTHS AND LIMITATIONS
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: ACUTE DECOMPENSATED HEART FAILURE (ADHF) (Published on 15 February 2018)

  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • DIURETICS
  • VASODILATORS
  • INOTROPIC AGENTS
  • OTHER DRUG CLASSES
  • PRODUCT PROFILE: NATRECOR
  • PRODUCT PROFILE: SIMDAX

PIPELINE: ACUTE DECOMPENSATED HEART FAILURE (ADHF) (Published on 15 February 2018)

  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • RECENTLY DISCONTINUED DRUGS
  • PRODUCT PROFILE (LATE STAGE): BMS-986231

LIST OF FIGURES

  • Figure 1: Typical treatment flow for initial management of a patient hospitalized with suspected ADHF
  • Figure 2: Clinical profiles of patients with acute heart failure based on the presence/absence of congestion and/or hypoperfusion
  • Figure 3: Percentage of ADHF patients receiving each treatment type, by country
  • Figure 4: Percentage of ADHF patients receiving each type of non-pharmacological therapy, by country
  • Figure 5: Percentage of first-line ADHF regimens containing each drug class, by country
  • Figure 6: Use of each diuretic class as a percentage of total diuretic use for the first-line treatment of ADHF, by country
  • Figure 7: Use of each vasodilator as a percentage of total vasodilator use for the first-line treatment of ADHF, by country
  • Figure 8: Use of each inotropic agent as a percentage of total inotropic use for the first-line treatment of ADHF, by country
  • Figure 9: Percentage of regimens for the treatment of ADHF containing Entresto, by line of therapy and country
  • Figure 10: Top three first-line regimens for ADHF, by country
  • Figure 11: Percentage of ADHF patients moving on to second-line therapy who were responsive or non-responsive to firstline therapy, by country
  • Figure 12: Percentage of second-line ADHF regimens containing each drug class for patients who show a response to firstline treatment, by country
  • Figure 13: Percentage of second-line ADHF regimens containing each drug class for patients who do not show a response to first-line treatment, by country
  • Figure 14: Trend in diagnosed incident cases of ADHF in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 15: Absolute change in diagnosed incident cases of ADHF in the US, Japan, and five major EU markets, by country, 2016-36
  • Figure 16: Natrecor for ADHF - SWOT analysis
  • Figure 17: Datamonitor Healthcare's drug assessment summary for Natrecor in ADHF
  • Figure 18: Datamonitor Healthcare's drug assessment summary for Natrecor in ADHF
  • Figure 19: Simdax for ADHF - SWOT analysis
  • Figure 20: Datamonitor Healthcare's drug assessment summary of Simdax for ADHF
  • Figure 21: Datamonitor Healthcare's drug assessment summary of Simdax for ADHF
  • Figure 22: BMS-986231 for ADHF - SWOT analysis
  • Figure 23: Datamonitor Healthcare's drug assessment summary of BMS-986231 for ADHF
  • Figure 24: Datamonitor Healthcare's drug assessment summary of BMS-986231 for ADHF

LIST OF TABLES

  • Table 1: Cardiologists surveyed for the ADHF primary research study, 2017
  • Table 2: Common triggers of ADHF
  • Table 3: Mean percentage of ADHF patients who have risk factors/co-morbidities in the US, Japan, and five major EU markets, by country
  • Table 4: Treatments available for ADHF across the US, Japan, and five major EU markets
  • Table 5: Percentage of first-line ADHF regimens containing each drug class, by country
  • Table 6: Sources used for the epidemiological analysis of ADHF in the US, Japan, and five major EU markets, by country
  • Table 7: Diagnosed incident cases of ADHF in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 8: Age-specific diagnosed incident cases of ADHF in the US, Japan, and five major EU markets, by country, 2016
  • Table 9: Gender-specific diagnosed incident cases of ADHF in the US, Japan, and five major EU markets, by country, 2016
  • Table 10: Profiled key marketed drugs for ADHF
  • Table 11: Diuretics class overview
  • Table 12: Vasodilators class overview
  • Table 13: Inotropic agents class overview
  • Table 14: Other drug classes overview
  • Table 15: Natrecor drug profile
  • Table 16: Natrecor Phase III data in ADHF
  • Table 17: Simdax drug profile
  • Table 18: Simdax Phase III data in ADHF
  • Table 19: Profiled pipeline products in development for ADHF
  • Table 20: Late-stage compounds that were recently discontinued for ADHF
  • Table 21: Reasanz drug profile
  • Table 22: Ularitide drug profile
  • Table 23: BMS-986231 drug profile
  • Table 24: BMS-986231 Phase II data in ADHF
  • Table 25: BMS-986231 Phase II trials in ADHF
Back to Top